Safety and Efficacy Study of Engensis (VM202) in the Treatment of Chronic Non-Healing Foot Ulcers

NCTID	NCT02563522 (View at clinicaltrials.gov)
Description	This study will assess the safety and efficacy of using gene therapy via intramuscular injections of the calf for patients with chronic non-healing foot ulcers. (Show More)
Development Status	Active
Indication	Diabetic Foot Ulcer
Disease Ontology Term	DOID:8529
Compound Name	ENGENSIS
Compound Alias	donaperminogene seltoplasmid, VM202
Compound Description	pCK-HGF-X7 (HGF 728, HGF723 isoforms)
Sponsor	Helixmith Co., Ltd.
Funder Type	Industry
Recruitment Status	Terminated
Enrollment Count	44
Results Posted	View Results

Target Gene/Variant	HGF
Therapy Type	Gene transfer
Therapy Route	In-vivo
Mechanism of Action	Overexpression of protective allele/gene
Route of Administration	Intramuscular (gastrocnemius)
Drug Product Type	Plasmid
Target Tissue/Cell
Delivery System	None (naked plasmid)
Vector Type
Editor Type
Dose 1	4mg (dose/day) * 4 treatment days
Dose 2
Dose 3
Dose 4
Dose 5

No.of Trial Sites	22
Locations	United States